COMMUNIQUÉS West-GlobeNewswire
-
Thousands of Free HIV Tests to Support National HIV Testing Day Activities Across the United States
23/06/2026 -
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
23/06/2026 -
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
23/06/2026 -
Integra LifeSciences Announces Key Executive Appointments
23/06/2026 -
UREVO Mid-Year Sale Brings 2026's Biggest Deal Yet to Amazon and Official Website
23/06/2026 -
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026 -
Advanced Rehabilitation, LLC Expands iKNOT Curriculum to Address Complex Regional Pain Syndrome & Chronic Upper Extremity Problems
23/06/2026 -
Avalo Therapeutics Appoints Ron Philip to Board of Directors
23/06/2026 -
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
23/06/2026 -
Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug Design
23/06/2026 -
ApolloMD Welcomes 2026 Emergency Medicine Administrative Fellows and Opens Applications for Next Class
23/06/2026 -
Plus Therapeutics to Provide Business Update Call on June 30, 2026
23/06/2026 -
Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
23/06/2026 -
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
23/06/2026 -
Soleo Health Named URAC Performance Measurement Pioneer for Second Consecutive Year
23/06/2026 -
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
23/06/2026 -
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
23/06/2026 -
Transactions in connection with share buy-back program
23/06/2026 -
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
23/06/2026
Pages